Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial
JMIR Formative Research · 2026
DOI: 10.2196/86149 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Formative Research, 2026. Verfasst von Narawitch Sompornpailin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangk…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Chemotherapy-related toxicities often lead to unscheduled health care use and diminished quality of life. Digital health interventions, such as chatbots, offer a scalable solution for supportive care; however, evidence regarding their effectiveness in resource-limited, low- and middle-income settings remains limited.
Objective
This study aimed to evaluate the feasibility, use, and preliminary effectiveness of a closed-loop chatbot (ChulaCancer Chatbot) in reducing unscheduled hospital visits and stabilizing quality of life among patients receiving chemotherapy for breast or colorectal cancer.
Methods
This pilot randomized controlled trial enrolled 40 patients at a single academic center in Thailand, randomized 1:1 to either ChulaCancer chatbot plus usual care or usual care alone. The primary end point was the proportion of unscheduled hospital visits due to chemotherapy-related toxicities within 12 weeks of treatment initiation. Secondary end points included longitudinal quality of life changes (30-item EORTC Quality of Life Questionnaire) measured at baseline, following chemotherapy cycle 2, and following cycle 4. Use metrics were extracted from the chatbot platform. Data were analyzed using the Fisher exact test and linear mixed-effects models.
Results
The platform recorded 2393 total messages with a 70.5% (503/713) successful response rate for user-initiated queries. Unscheduled hospital visits occurred in 15% (3/20) of the chatbot group compared to 35% (7/20) of the usual care group (P=.24). While infection-related visits were similar between groups, the usual care group recorded multiple visits for low-acuity symptoms (eg, anxiety, headache, and edema) that were absent in the chatbot group. Regarding quality of life, the chatbot group demonstrated a significant mitigation of cancer-related fatigue following cycle 4 compared with the usual care group (P=.02 between groups). Additionally, the chatbot group significantly improved in global health status (P=.04) and avoided the decline in physical functioning observed in the control arm (P=.04).
Conclusions
The integration of a closed-loop chatbot into oncology care is feasible and provides a potential secure triage mechanism that may reduce acute care use for low-acuity concerns. Future large-scale trials incorporating agentic artificial intelligence are warranted to further validate clinical and economic benefits. Trial Registration Thai Clinical Trials Registry TCTR20251220014; https://tinyurl.com/5b6k3e63
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University & The King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Pharmacy Department, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
ORCID-Profile: Narawitch Sompornpailin, Thiti Susiriwatananont, Virote Sriuranpong, Suebpong Tanasanvimon, Chanida Vinayanuwattikun, Piyada Sitthideatphaiboon, Nattaya Poovorawan, Nattaya Teeyapun, Nicha Zungsontiporn, Nussara Pakvisal, Poonnakarn Panjasriprakarn, Bussaba Trakarnsanga, Napa Parinyanitikul
Zitieren
APA
Sompornpailin, N., Susiriwatananont, T., Sriuranpong, V., Tanasanvimon, S., Vinayanuwattikun, C., Sitthideatphaiboon, P., Poovorawan, N., Teeyapun, N., Zungsontiporn, N., Pakvisal, N., Panjasriprakarn, P., Trakarnsanga, B., & Parinyanitikul, N. (2026). Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial. JMIR Formative Research. https://doi.org/10.2196/86149
Vancouver
Sompornpailin N, Susiriwatananont T, Sriuranpong V, Tanasanvimon S, Vinayanuwattikun C, Sitthideatphaiboon P, et al. Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial. JMIR Formative Research. 2026. doi:10.2196/86149
BibTeX
@article{Sompornpailin2026,
author = {Sompornpailin, Narawitch and Susiriwatananont, Thiti and Sriuranpong, Virote and Tanasanvimon, Suebpong and Vinayanuwattikun, Chanida and Sitthideatphaiboon, Piyada and Poovorawan, Nattaya and Teeyapun, Nattaya and Zungsontiporn, Nicha and Pakvisal, Nussara and Panjasriprakarn, Poonnakarn and Trakarnsanga, Bussaba and Parinyanitikul, Napa},
title = {Feasibility and Preliminary Effectiveness of the ChulaCancer Mobile Chatbot for Supportive Care of Patients With Breast or Colorectal Cancer Receiving Chemotherapy: Pilot Randomized Controlled Trial},
journal = {JMIR Formative Research},
year = {2026},
doi = {10.2196/86149}
}
EUVIMED